# Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

> **NCT03212404** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Checkpoint Therapeutics, Inc.** · enrollment: 272 (actual)

## Conditions studied

- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Small Cell
- Malignant Mesothelioma, Advanced
- Head and Neck Cancer
- Melanoma
- Merkel Cell Carcinoma
- Renal Cell Carcinoma
- Urothelial Carcinoma
- Classical Hodgkin Lymphoma
- Cutaneous Squamous Cell Carcinoma
- Non Hodgkin Lymphoma
- Endometrial Cancer

## Interventions

- **DRUG:** CK-301 (cosibelimab)

## Key facts

- **NCT ID:** NCT03212404
- **Lead sponsor:** Checkpoint Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-09-20
- **Primary completion:** 2021-11-18
- **Final completion:** 2025-12
- **Target enrollment:** 272 (ACTUAL)
- **Last updated:** 2025-02-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03212404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03212404, "Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03212404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*